1.Xiaopeng Peng, Wanyi Pan, Feng Jiang, Weiming Chen, Zetao Qi, Weijie Peng, Jianjun Chen, Selective PARP1 inhibitors, PARP1-based dual-target inhibitors, PROTAC PARP1 degraders, and prodrugs of PARP1 inhibitors for cancer therapy, Pharmacological Research 186 (2022)...
参考文献: [1]CT014.PETRA: first-in-human Phase 1/2a trial of the first-in-class next-generation poly(ADP-ribose) polymerase-1 selective inhibitor (PARP1i) saruparib (AZD5305) in patients (pts) with advanced solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations.2024 AACR. 编辑:KI...
参考文献: [1]CT014.PETRA: first-in-human Phase 1/2a trial of the first-in-class next-generation poly(ADP-ribose) polymerase-1 selective inhibitor (PARP1i) saruparib (AZD5305) in patients (pts) with advanced solid tumors with BR...
AZD5305 did not sensitize PDXs with acquired resistance to olaparib but elicited profound and durable responses when combined with carboplatin or ceralasertib in 3/6 and 5/5 models, respectively.Collectively, these results show that the novel PARP1 selective inhibitor AZD5305 yields a potent ...
Founded in April 2020, DigmBio is a pioneering biotech company discovering and developing novel therapies to treat oncology, neurodegeneration, and fibrosis. The lead program DM5167 is the 2nd generation PARP1 selective inhibitor. According to preclinical study results,DM5167, a novel selective PARP1...
G2019S selective LRRK2 kinase inhibitor abrogates mitochondrial DNA damage Article Open access 01 March 2024 Data availability The MS data have been deposited in the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifiers PXD014838 (Supplementary Dataset 1), PXD014836...
Current status and future promise of next-generation poly (ADP-Ribose) polymerase 1-selective inhibitor AZD5305 improved selectivity for PARP1, expanding significant clinical values and wide application prospects both in monotherapy and combination with other anticancer ... J Zheng,Z Li,W Min - 《...
PARP1/c-Met-IN-1 (Compound 16) serves as a selective dual inhibitor targeting both PARP1 and c-Met, demonstrating IC50 values of 3.3 nM and 32.2 nM, respectively. This compound effectively induces apoptosis and causes cell cycle arrest at the G2/M phase in MDA-MB-231 cells. Furthermore...
PARP1-IN-5 is a potent, selective, orally active, low-toxicity PARP-1 inhibitor with an IC50 value of 14.7 nM. PARP1-IN-5 can be used in cancer research. 化学信息 分子量 464.53 分子式 C25H24N2O5S 储存&溶解度 存储 Shipping with blue ice. ...
2.Giuditta Illuzzi, Anna D Staniszewska, et.al, Preclinical Characterization of AZD5305, A Next-Generation, Highly Selective PARP1 Inhibitor and Trapper, Clin Cancer Res. 2022 Nov 1;28(21):4724-4736. 【企业推荐】